The American Autoimmune Related Diseases Association (AARDA), other patient advocates and providers understand that UnitedHealthcare intends to move Remicade from preferred to non-preferred coverage in February 2021. This abrupt change by the plan could be disruptive to stable patients and their care, and undermines the treatment regimen set by patients and their prescriber. We ask that you amend this decision by granting prescribers the ability to keep patients on a specific medication if they determine it to be medically necessary.
